Steven Kelly
Chief Executive Officer bei CARISMA THERAPEUTICS, INC.
Vermögen: 1 118 $ am 30.04.2024
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Gregory Gorgas | M | 61 | 7 Jahre | |
Michael Klichinsky | M | 34 |
CTx Operations, Inc.
CTx Operations, Inc. BiotechnologyHealth Technology CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA. | 8 Jahre |
Richard Morris | M | 51 |
CTx Operations, Inc.
CTx Operations, Inc. BiotechnologyHealth Technology CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA. | 3 Jahre |
Sanford Zweifach | M | 68 |
CTx Operations, Inc.
CTx Operations, Inc. BiotechnologyHealth Technology CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA. | 3 Jahre |
Björn Ingemar Odlander | M | 66 |
CTx Operations, Inc.
CTx Operations, Inc. BiotechnologyHealth Technology CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA. | 2 Jahre |
Regina Hodits | M | 53 |
CTx Operations, Inc.
CTx Operations, Inc. BiotechnologyHealth Technology CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA. | 6 Jahre |
Briggs Morrison | M | 65 |
CTx Operations, Inc.
CTx Operations, Inc. BiotechnologyHealth Technology CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA. | 4 Jahre |
Chidozie Ugwumba | M | 41 |
CTx Operations, Inc.
CTx Operations, Inc. BiotechnologyHealth Technology CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA. | 4 Jahre |
Eric Siegel | M | 60 | 1 Jahre | |
Jason Baybutt | M | 52 | 2 Jahre | |
Douglas Blayney | M | 73 | 7 Jahre | |
Michael Torok | M | 45 | 1 Jahre | |
Connie Matsui | F | 70 | 7 Jahre | |
Gregory Reyes | M | 70 | 4 Jahre | |
Tamara Favorito | F | 65 | 3 Jahre | |
Robert Emanuele | M | 69 | 7 Jahre | |
Margarita I. Chavez | F | - |
CTx Operations, Inc.
CTx Operations, Inc. BiotechnologyHealth Technology CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA. | - |
Daniel Cushing | M | - | 7 Jahre | |
John Hohneker | M | 64 | - | |
Steven D. Reich | M | - | 6 Jahre | |
Andy Yates | M | - | 3 Jahre | |
Sascha Abramson | M | - |
CTx Operations, Inc.
CTx Operations, Inc. BiotechnologyHealth Technology CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA. | - |
Lin Guey | F | - |
CTx Operations, Inc.
CTx Operations, Inc. BiotechnologyHealth Technology CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA. | 1 Jahre |
Terry Shields | F | - | 1 Jahre | |
Tom Wilton | M | - | 5 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Peter O’Brien | M | 45 | 5 Jahre | |
Debora Barton | M | 48 |
CTx Operations, Inc.
CTx Operations, Inc. BiotechnologyHealth Technology CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA. | 3 Jahre |
Eric Poma | M | 52 |
Innovive Pharmaceuticals, Inc.
Innovive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is developing compounds for the treatment of cancer. It currently have four products in development; INNO-406, tamibarotene, INNO-206 and INNO-406. The Group operates in the United States of America. | - |
John W. Beck | M | 64 | 2 Jahre | |
Georgia Erbez | F | 57 | 2 Jahre | |
Robert G. Petit | M | 64 |
CTx Operations, Inc.
CTx Operations, Inc. BiotechnologyHealth Technology CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA. | - |
Randy Schreckhise | M | - | 2 Jahre | |
Ross Leimberg | M | - |
CTx Operations, Inc.
CTx Operations, Inc. BiotechnologyHealth Technology CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA. | 4 Jahre |
Philip Frost | M | 84 |
Innovive Pharmaceuticals, Inc.
Innovive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is developing compounds for the treatment of cancer. It currently have four products in development; INNO-406, tamibarotene, INNO-206 and INNO-406. The Group operates in the United States of America. | 3 Jahre |
Angelo de Caro | M | 81 |
Innovive Pharmaceuticals, Inc.
Innovive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is developing compounds for the treatment of cancer. It currently have four products in development; INNO-406, tamibarotene, INNO-206 and INNO-406. The Group operates in the United States of America. | 1 Jahre |
Michael Dowd | M | - |
Innovive Pharmaceuticals, Inc.
Innovive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is developing compounds for the treatment of cancer. It currently have four products in development; INNO-406, tamibarotene, INNO-206 and INNO-406. The Group operates in the United States of America. | - |
J. Lobell | M | 61 |
Innovive Pharmaceuticals, Inc.
Innovive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is developing compounds for the treatment of cancer. It currently have four products in development; INNO-406, tamibarotene, INNO-206 and INNO-406. The Group operates in the United States of America. | 2 Jahre |
Antony Pfaffle | M | 60 |
Innovive Pharmaceuticals, Inc.
Innovive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is developing compounds for the treatment of cancer. It currently have four products in development; INNO-406, tamibarotene, INNO-206 and INNO-406. The Group operates in the United States of America. | 2 Jahre |
Michael Heffernan | M | 59 |
CTx Operations, Inc.
CTx Operations, Inc. BiotechnologyHealth Technology CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA. | - |
Neil Herskowitz | M | 67 |
Innovive Pharmaceuticals, Inc.
Innovive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is developing compounds for the treatment of cancer. It currently have four products in development; INNO-406, tamibarotene, INNO-206 and INNO-406. The Group operates in the United States of America. | 2 Jahre |
J. Gregory Jester | M | 56 |
Innovive Pharmaceuticals, Inc.
Innovive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is developing compounds for the treatment of cancer. It currently have four products in development; INNO-406, tamibarotene, INNO-206 and INNO-406. The Group operates in the United States of America. | 4 Jahre |
Adam Craig | M | 58 |
Innovive Pharmaceuticals, Inc.
Innovive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is developing compounds for the treatment of cancer. It currently have four products in development; INNO-406, tamibarotene, INNO-206 and INNO-406. The Group operates in the United States of America. | 2 Jahre |
Jacob Uno Stanley Gunterberg | M | 57 |
CTx Operations, Inc.
CTx Operations, Inc. BiotechnologyHealth Technology CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA. | - |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 43 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Steven Kelly
- Persönliches Netzwerk